About US
Contact us
-
EMA accepts Pfizer's filing of axitinib for regulatory review to treat advanced renal cell carcinomaPfizer Inc. announced today that the European Medicines Agency (EMA) has accepted Pfizer's filing for regulatory review of axitinib for patients with advanced renal cell carcinoma (RCC) after failure2011/6/2
-
China's SFDA grants production license to TPI anti-diabetic drug GliclazideTianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and other2011/6/2
-
Four departments require to further crack down on releasing false drug information and selling drugs illegally over the InternetIn order to consolidate the rectification achievements, continuously intensify the crackdown on releasing false drug information and selling drugs illegally over the Internet, and maintain strict supe2011/6/1
-
FDA approves Actavis’ Donepezil Hydrochloride 5mg and 10mg tabletsActavis, an international generic pharmaceutical company, today announced that it has received approval from the US Food & Drug Administration to market Donepezil Hydrochloride Tablets a generic e2011/6/1
-
Cancer drug helps prevent hypertensive heart diseaseA promising cancer treatment drug can restore function of a heart en route to failure from high blood pressure, researchers at UT Southwestern Medical Center have found. The drug, a type of histone2011/5/31
-
Optimer receives FDA approval for Dificid tablets to treat C. difficile-associated diarrheaThe U.S. Food and Drug Administration today approved Dificid (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD). Clostridium difficile (C. difficile) is a b2011/5/30
-
Emergent in active discussions with U.S. government for multi-year supply of BioThrax to the SNSEmergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. government has indicated its intention to award Emergent a sole source contract (RFP-2011-N-13414) for the purchase of 44.75 million2011/5/30
-
Bayer, Epitomics enter service agreement for antibody technologyEpitomics, Inc. announced today that it has signed a service agreement with Bayer Schering Pharma AG, Germany (Bayer HealthCare). Epitomics will use its proprietary rabbit monoclonal antibody technolo2011/5/27
-
PAREXEL, Pfizer partner to execute clinical development programs on global basisPAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that it has been selected as one of two strategic partners by Pfizer Inc. to pro2011/5/27
-
The revised Provisions for Adverse Drug Reaction Reporting and Monitoring issuedThe newly revised Provisions for Adverse Drug Reaction Reporting and Monitoring was issued on May 24, 2011, and will be put into force on July 1, 2011. The revised Provisions for Adverse Drug Reactio2011/5/26